The therapeutic application of C-500 (Sodium Ascorbate) is generally centered on correcting essential nutrient status, providing support that helps ease symptoms related to systemic imbalance. This compound is considered relevant for managing conditions associated with its deficiency.

C-500 is commonly used across conditions presenting with acute episodes of deficiency, including Scurvy and hypovitaminosis C, and is applied in scenarios requiring additional symptomatic assistance during phases of physical recovery. This preparation helps address symptom clusters related to physical discomfort, such as bleeding gums, easy bruising, and compromised wound healing.

Core Symptomatic Support

It also supports patients during episodes of heightened discomfort by addressing persistent fatigue and general malaise, particularly when driven by nutrient insufficiency. This use is relevant for managing symptoms that interfere with daily comfort, and assists with maintaining functional stability.

Quick Fact: Support for Symptoms related to Tissue Health The use of C-500 is relevant for easing symptoms like capillary fragility and gingivitis, contributing to improved comfort and supports general well-being during periods of nutritional strain.

C-500 (Ascorbic Acid or Vitamin C) is generally intended for use by the general population to prevent or treat vitamin C deficiency (scurvy) at recommended daily doses. Official regulatory documents establish specific groups for whom use is contraindicated or requires caution.

Eligibility Restrictions

Contraindications:

• Known hypersensitivity or allergic reaction to ascorbic acid or any component of the formulation.

Use Requires Caution/Not Recommended:

• Renal Impairment or History of Kidney Stones (Nephrolithiasis): High doses (typically above 1,000 mg/day) may increase the risk of forming calcium oxalate stones or lead to oxalate nephropathy.
• Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency: High-dose use, particularly intravenous formulations, carries a risk of severe hemolytic anemia (destruction of red blood cells).
• Iron Overload Conditions: Patients with conditions like hemochromatosis, thalassemia, or sideroblastic anemia should minimize intake, as ascorbic acid enhances iron absorption, which can be dangerous.
• Pregnancy and Lactation: Use of the medicine is generally considered acceptable within the normal recommended daily allowance. High-dose use (e.g., above 1,000 mg daily) is not recommended during pregnancy unless medically indicated.

For any pre-existing medical conditions, including diabetes or certain blood disorders, consultation with a healthcare professional is necessary to determine eligibility and appropriate dosage.

Interactions with other medicines and products

The official regulatory profile for C-500 (Sodium Ascorbate) documents several distinct interaction patterns, categorized based on pharmacokinetic effects, pharmacodynamic changes, and chemical incompatibility.

---

Interaction Restrictions and Classifications

Certain combinations are subject to formal regulatory restrictions. Bleomycin is restricted due to a risk of in vitro inactivation by Ascorbic Acid, and Copper compounds are listed as chemically incompatible in solution.

---

Pharmacokinetic and Exposure Effects

C-500 can influence drug elimination through its effect on urine acidity. As a urine acidifier, it may cause a pharmacokinetic interaction that decreases the serum concentration of basic drugs, such as Amphetamine, by increasing their renal excretion. Conversely, co-administration with Paracetamol has been officially described as prolonging the presence of the analgesic in the blood.

---

Pharmacodynamic and Absorption Changes

A significant documented pharmacodynamic interaction is the ability of C-500 to increase the absorption of elemental iron from the gastrointestinal tract. Furthermore, the activity of certain antibiotics, including Erythromycin, may be decreased when co-administered.

---

Population-Specific Note

An explicit interaction-related caution exists for patients with Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency, where high-dose administration carries a documented risk of severe hemolysis. No mandatory timing separation rules for oral dosing are officially listed in primary regulatory labels.

How C-500 Works: Mechanistic Principles

C-500, which supplies Ascorbic Acid, exerts its physiological effects primarily through two fundamental biochemical roles: as a required enzyme cofactor and a systemic antioxidant. The compound does not act as a ligand for classical membrane receptors.

Cofactor Role in Collagen Biosynthesis

The molecule acts as a reducing agent essential for maintaining the ferrous ( Fe^2+) state of hydroxylase enzymes, specifically Prolyl Hydroxylase and Lysyl Hydroxylase. This cofactor role is mandatory for the post-translational hydroxylation of procollagen, enabling the formation of the molecule's triple helix. This mechanism results in the formation of stabilized collagen fibers in the extracellular matrix (ECM) of structures such as blood vessels and bone.

Systemic Contribution to Redox Homeostasis

Functioning as a water-soluble antioxidant, Ascorbic Acid readily donates electrons to quench Reactive Oxygen Species (ROS). This action neutralizes free radicals, limiting their interaction with cellular components, including DNA, lipids, and proteins. Concurrently, the molecule facilitates the synthesis of key molecules, notably the neurotransmitter Norepinephrine and the metabolic transporter Carnitine, supporting neurotransmission and facilitating fatty acid energy utilization.

The administration of C-500 (Sodium Ascorbate or Ascorbic Acid) is characterized by different routes for maintenance versus the correction of acute deficiency states. For routine prophylaxis and general essential nutrient support, the medicine is typically administered via the oral route in tablet or capsule form. Oral preparations may generally be taken with or without food.

When utilized for the therapeutic management of a confirmed deficiency, the medicine follows a specific dosing schedule for a short-term course that lasts a minimum of two weeks. The dose is standardized and administered once daily, with amounts scaled by the patient’s age. The intravenous (IV) route is specified for cases of severe deficiency or malabsorption. The adult dose for this therapeutic IV use is 200 mg per day, while doses for infants (e.g., 5 to 12 months) are 50 mg per day.

The IV administration route requires specialized preparation: the concentrated injectable solution must be diluted in an appropriate infusion solution before being administered as a slow intravenous infusion. Furthermore, the injectable preparation requires protection from light to maintain potency. A specific constraint in administration dictates that for patients with severe renal impairment, the daily intake is restricted to 50 mg to 100 mg. This structured approach ensures that the administration method, dose, and frequency align with the established parameters for this essential nutrient preparation.

Research evidence / Overview of studies for C-500

Evidence for the Correction of Acute Deficiency (Scurvy)

The historical research base for C-500 is foundational to the study of its role in conditions associated with severe nutrient shortage. Studies for acute deficiency, like Scurvy, include early controlled intervention studies and extensive historical case reports. This research primarily examined populations exhibiting certain physical signs of deficiency, such as bleeding gums and easy bruising. Outcomes monitored involved patterns related to the evolution of these physical manifestations, alongside measuring the restoration of plasma nutrient levels.

The evidence contributes to observed data on symptom patterns, with studies reporting a short-term pattern of change in the acute phase of deficiency. These studies describe how the physical signs of deficiency evolved in the observed populations following the administration of the compound. However, due to the established nature of nutrient repletion as a required treatment, contemporary, large-scale Randomized Controlled Trials (RCTs) are limited. Research focusing on the long-term status beyond the initial correction is not well characterized in this foundational evidence base.

Evidence for Status Management (Hypovitaminosis C)

Research exploring the study of C-500 for nutrient status management, often called Hypovitaminosis C or insufficiency, relies on observational cohort studies and comprehensive systematic reviews of dietary intake. These studies have evaluated individuals whose dietary habits or underlying health issues put them at risk for lower nutrient levels. Research examined various outcomes related to systemic or functional imbalance, including persistent fatigue and general malaise, alongside monitoring nutrient biomarker status.

Findings describe patterns observed in the studies related to nutrient biomarker changes following administration. The evidence contributes to the broader landscape of observed data on the compound's role as an essential nutrient, and trials have explored its role in assessing short-term or episodic symptom patterns linked to deficiency. However, findings were sometimes mixed or varied, as the measured outcomes are often complicated by the presence of other dietary co-factors. Furthermore, the definition of what constitutes 'insufficiency' remains inconsistent across different research studies.

Key Studies & References The Effects of Vitamin C on Wound Healing—Systematic Review

Common questions about C-500 (FAQ)

Q: Can C-500 be used by people who are 65 or older?

A: Official sources, such as those detailing geriatric use, indicate that problems have not been reported in older adults when the compound is taken within the normal daily recommended amounts. Official information does not indicate specific restrictions for this age group, but notes that individual health status is always a factor.

Q: What is the general safety classification of C-500 (e.g., pregnancy category)?

A: The safety classification for use during pregnancy is dose-dependent. Doses within the typical Recommended Dietary Allowance (RDA) are classified as Category A. However, doses that exceed the RDA are generally classified as Category C.

Q: Can C-500 be used by children?

A: Yes, official information indicates that C-500 can be used by younger patient groups. Recommended daily doses for different age ranges, including infants, children, and adolescents, are established by authoritative sources for the purpose of dietary supplementation.

Q: Is C-500 generally taken long-term or short-term?

A: The duration of use can vary based on the physiological need, as the official indications include both short-term treatment of deficiency and long-term prophylaxis (prevention). Regulatory warnings note that prolonged, high intake can alter how the body manages the compound; rapidly reducing the product might cause a deficiency state.

Q: Is C-500 considered a preventative medicine?

A: Yes, according to official product information, the primary indications for C-500 include the prophylaxis (prevention) of Vitamin C deficiency, commonly known as scurvy. It is also indicated for the treatment of an existing deficiency.

Q: Are there different forms of C-500 (e.g., tablet, liquid, extended-release)?

A: Official documents confirm that C-500 is available in several dosage forms. These commonly include oral tablets or chewable tablets, capsules, and specialized solutions for injection, as listed in the official documents for the product.

Q: Are there any requirements for monitoring (like blood tests) while on C-500?

A: Routine blood monitoring is typically not addressed in official documents for general use. However, regulatory warnings note that specific monitoring may be warranted for patients with pre-existing conditions like a history of hyperoxaluria (high oxalate levels) or those taking certain medications, as these factors can influence risk.

Q: What happens if too much C-500 is taken?

A: Regulatory documents caution that massive overdosage has been associated with the potential for renal failure (kidney failure). Official guidance notes that general supportive medical measures are utilized in cases of massive overdosage.

Q: Do official documents mention any potential for withdrawal symptoms with C-500?

A: Official warnings address the concept of deficiency after cessation of high intake. After prolonged periods of high intake, the body's method of eliminating the compound can change. Therefore, rapidly reducing or entirely withdrawing the product might lead to a state of deficiency due to this increased rate of clearance.

Q: Are there any specific foods or drinks that should be avoided with C-500?

A: Official interaction data notes that certain compounds may be affected. Concomitant use with aluminium-containing antacids is generally not recommended, especially for individuals with renal issues. The compound is also officially documented to increase the oral absorption of iron.

Q: Does C-500 interact with birth control pills?

A: Yes, regulatory documents describe a potential interaction. The plasma concentration of the active ingredient in C-500 may be decreased by oral contraceptives. Additionally, taking high doses of C-500 has been associated with potentially increasing serum estrogen levels.

Q: Are there any known interactions with alcohol consumption while using C-500?

A: Official documents indicate that alcohol consumption is associated with reducing the body's ascorbic acid levels. This effect can lead to tissue desaturation and may impact the compound's overall effectiveness in the body.

Q: Can C-500 affect the results of lab tests?

A: Yes, regulatory sources warn that C-500 may interfere with certain laboratory tests. This interference can potentially cause false results for various measurements, such as urinary glucose, uric acid, and creatinine. The potential for interference means that clinical laboratories may need to be aware of the patient's intake status.

Q: How is the term 'benefit' defined for C-500 in clinical trials?

A: The benefits described in official documents are defined by the compound's established physiological roles in the body. This includes its function as a systemic antioxidant, its necessity as a cofactor for enzymes involved in collagen and connective tissue formation, and its support for other enzyme systems.

Official Storage and Disposal Requirements

The official labeled instructions define specific environmental controls necessary to maintain the stability of C-500 (Ascorbic Acid/Sodium Ascorbate). The medicine must be stored at a controlled room temperature, generally between 20 C and 25 C, and storage must not exceed 30 C.

Protection and Handling

C-500 must be kept in its original container and the container must remain tightly closed to provide protection from light and excess moisture. This environmental protection is mandatory to ensure the product remains stable until the stated expiry date. Like all medicines, C-500 must be stored out of the sight and reach of children.

Disposal of Unused Medicine

Regulatory guidelines specify that unused or expired C-500 must not be thrown away in household garbage or disposed of via wastewater. Users are instructed to consult a pharmacist or local authority for guidance on appropriate pharmaceutical waste disposal to comply with environmental regulations.